Recently, CSL Limited (ASX: CSL) has announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA (C1 Esterase Inhibitor Subcutaneous), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. HAE is a rare, genetic, and potentially life-threatening condition that causes painful, debilitating, and unpredictable episodes of swelling on the body, including the abdomen, face, larynx, and extremities. HAEGARDA is a self-administered, plasma-derived concentrate of C1 esterase inhibitor (C1-INH) injected twice weekly subcutaneously. Notably, the FDA approval of HAEGARDA is an important milestone for the HAE community because it addresses the primary need of patients to effectively prevent debilitating HAE attacks. The stock has moved up 37.5% in last six months (as at July 03, 2017) and is trading near its 52-week elevated levels.